Dear colleagues and friends,
Incidence of valvular heart diseases keeps increasing along with the aging trend of the world, and makes it a serious threat to human health. As the evidence accumulates, transcatheter valvular replacement or repair emerged as an alternative for traditional cardiac surgery, especially in the field of transcatheter aortic valve replacement (TAVR). However, development of transcatheter valvular treatment in China is still at the initial status. There is an urgent call for systemic training for Chinese interventional cardiologists and their heart valve teams.
To improve transcatheter valvular treatment in China and international collaboration in the field, the third China Valve (Hangzhou) congress will be held on 14th to 16th April 2017. This year, we will continuously work with the support of CSI to provide a broader global vision, an improved training course and a deeper communicative platform. The program will include step by step learning from recorded cases, live cases, hands-on sessions, imaging training, up-to-date clinical trials and debates on hot spots, etc.
Hangzhou is an ancient, yet highly civilized city rich in both historical sites and natural landscapes, such as the West Lake and Grand Canal. The city is also an international metropolis where the G20 summit held in September 2016. You will have the opportunity to enjoy the wonderful scenery after scientific activities.
Welcome to Hangzhou!